UnitedHealth's Catamaran deal meant to combat rising drug costs

UnitedHealth will muscle up in its fight against rising specialty drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp. Companies like Catamaran help negotiate prices.

|
Jim Mone/AP/File
A portion of The UnitedHealth Group Inc.'s campus in Minnetonka, Minn. The nation’s largest health insurer, UnitedHealth, is staking a bigger claim in pharmacy benefits management with a plan to buy Catamaran Corp., for more than $12 billion in cash, the company announced, Monday, March 30, 2015.

The nation's largest health insurer, UnitedHealth, will muscle up in its fight against rising specialty drug costs by spending more than $12 billion to buy pharmacy benefits manager Catamaran Corp.

Pharmacy benefits managers, or PBMs, help negotiate the prices that customers pay for prescription drugs. They are seen as a key component in the push to contain rising specialty drug costs, an expense that could overwhelm parts of the health care system, especially the federal-state Medicaid program, insurers and other bill payers have warned.

Specialty drugs are complex medicines often represent treatment breakthroughs but come with much higher prices than older drugs. Experts say specialty drugs have always been pricey but confined to relatively small patient populations. That's changing, due in part to some relatively new hepatitis C treatments that could be used by millions of patients.

UnitedHealth and Catamaran said Monday that their deal will combine businesses that have "distinctive, rapidly growing specialty pharmacy services" for a segment of the market that is expected to quadruple from an estimated $100 billion in revenues last year to $400 billion by 2020.

UnitedHealth Group Inc.'s OptumRx PBM business fills about 600 million prescriptions annually. Catamaran expects to fill 400 million this year.

The nation's largest PBM, Express Scripts Holding Co., filled about 1.3 billion prescriptions last year.

Express Scripts executives have spoken out frequently about soaring costs from specialty drugs, and the St. Louis company threw its weight into this fight late last year by restricting coverage. It said in December it will no longer cover Sovaldi and Harvoni — two Gilead Sciences drugs that cost more than $80,000 each for a full course of treatment — or Johnson & Johnson's Olysio except under limited circumstances.

Instead, it made AbbVie Inc.'s Viekira Pak the preferred treatment for its patients.

PBMs can make these restrictions in part because of the leverage they get from the millions of customers they represent. Acquisitions have been a key means of growth in the sector for years.

In 2012, Express Scripts became the nation's largest PBM by completing a $29.1 billion acquisition of rival Medco Health Solutions. That same year, Catamaran changed its name from SXC Health Solutions after spending more than $4 billion to buy another PBM, Catalyst Health.

UnitedHealth said Monday that, for the latest deal, it will spend $61.50 in cash on each share of Catamaran. That's a 27 percent premium to Catamaran's closing price Friday.

Catamaran, based in Schaumburg, Illinois, had about 207.5 million shares outstanding at the end of January, which puts the deal price at roughly $12.76 billion.

The acquisition is expected to close during the fourth quarter.

Shares of Catamaran rose 24 percent, or $11.68, to $60 more than an hour before markets opened Monday. UnitedHealth, based in Minneapolis, also saw its shares climb 3.8 percent, or $4.49, to $122.50.

You've read  of  free articles. Subscribe to continue.
Real news can be honest, hopeful, credible, constructive.
What is the Monitor difference? Tackling the tough headlines – with humanity. Listening to sources – with respect. Seeing the story that others are missing by reporting what so often gets overlooked: the values that connect us. That’s Monitor reporting – news that changes how you see the world.

Dear Reader,

About a year ago, I happened upon this statement about the Monitor in the Harvard Business Review – under the charming heading of “do things that don’t interest you”:

“Many things that end up” being meaningful, writes social scientist Joseph Grenny, “have come from conference workshops, articles, or online videos that began as a chore and ended with an insight. My work in Kenya, for example, was heavily influenced by a Christian Science Monitor article I had forced myself to read 10 years earlier. Sometimes, we call things ‘boring’ simply because they lie outside the box we are currently in.”

If you were to come up with a punchline to a joke about the Monitor, that would probably be it. We’re seen as being global, fair, insightful, and perhaps a bit too earnest. We’re the bran muffin of journalism.

But you know what? We change lives. And I’m going to argue that we change lives precisely because we force open that too-small box that most human beings think they live in.

The Monitor is a peculiar little publication that’s hard for the world to figure out. We’re run by a church, but we’re not only for church members and we’re not about converting people. We’re known as being fair even as the world becomes as polarized as at any time since the newspaper’s founding in 1908.

We have a mission beyond circulation, we want to bridge divides. We’re about kicking down the door of thought everywhere and saying, “You are bigger and more capable than you realize. And we can prove it.”

If you’re looking for bran muffin journalism, you can subscribe to the Monitor for $15. You’ll get the Monitor Weekly magazine, the Monitor Daily email, and unlimited access to CSMonitor.com.

QR Code to UnitedHealth's Catamaran deal meant to combat rising drug costs
Read this article in
https://www.csmonitor.com/Business/2015/0330/UnitedHealth-s-Catamaran-deal-meant-to-combat-rising-drug-costs
QR Code to Subscription page
Start your subscription today
https://www.csmonitor.com/subscribe